Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICOM: Predictive Factors for IOP Reduction with Latanoprost/Timolol in Glaucoma/OHT
NCT00230763Phase 3Completed
- Sponsor
- Viatris
- Start
- Sep 2005
- Primary completion
- Oct 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of latanoprost and timolol in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Viatris. Primary endpoint: Percentage of patients with additional IOP reduction > 10% at 12 weeks. Started Sep 2005; status: completed.
02
Drugs
latanoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00230763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230763.